Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment
O Miltiadous, M Hou, JB Bussel - Blood, The Journal of the …, 2020 - ashpublications.org
Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
N Vianelli, G Auteri, F Buccisano, V Carrai… - Annals of …, 2022 - Springer
Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
C Neunert, W Lim, M Crowther, A Cohen… - Blood, The Journal …, 2011 - ashpublications.org
Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …
American Society of Hematology published a landmark guidance paper designed to assist …
Bleeding complications in immune thrombocytopenia
DM Arnold - Hematology 2014, the American Society of …, 2015 - ashpublications.org
Bleeding manifestations in patients with immune thrombocytopenia (ITP) range from mild
skin bruises to life-threatening intracranial hemorrhage (ICH). Severe bleeding is distinctly …
skin bruises to life-threatening intracranial hemorrhage (ICH). Severe bleeding is distinctly …
Update on diagnosis and treatment of immune thrombocytopenia
Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …
Current management of primary immune thrombocytopenia
D Provan, AC Newland - Advances in therapy, 2015 - Springer
Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …
both children and adults. The low peripheral blood platelet count is caused by premature …
[HTML][HTML] Treatments for primary immune thrombocytopenia: a review
M Samson, W Fraser, D Lebowitz - Cureus, 2019 - ncbi.nlm.nih.gov
Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)
PYI Choi, F Roncolato, X Badoux… - Blood, The Journal …, 2015 - ashpublications.org
Promising reports of combination immunosuppression with high-dose dexamethasone and
rituximab for the treatment of primary immune thrombocytopenia (ITP) have recently …
rituximab for the treatment of primary immune thrombocytopenia (ITP) have recently …
Immune thrombocytopenia
G Kistangari, KR McCrae - Hematology/Oncology Clinics, 2013 - hemonc.theclinics.com
Immune thrombocytopenia (ITP) is a common hematologic disorder that affects patient of all
ages, genders, and races. Initially known as idiopathic thrombocytopenic purpura, an …
ages, genders, and races. Initially known as idiopathic thrombocytopenic purpura, an …